PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27220321-7 2016 Additionally, pre-treatment with either EGFR kinase inhibitor PD153035 or ERK1/2 kinase inhibitor PD98059 in HCT116/5-FU cells partly inhibits P-glycoprotein expression and AP-1 binding activity (P < 0.05). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 62-70 epidermal growth factor receptor Homo sapiens 40-44 25550802-7 2014 The EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 27-35 epidermal growth factor receptor Homo sapiens 4-8 26986216-6 2016 Blocking the EGFR/MAPK pathway by its specific inhibitor PD153035 or EGFR small interfering RNA (siRNA) resulted in the reduced MDR of K562/ADR cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 57-65 epidermal growth factor receptor Homo sapiens 13-17 26334931-0 2016 Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 29-37 epidermal growth factor receptor Homo sapiens 54-58 26334931-6 2016 HCC827 and PC9 cells, which were highly sensitive to EGFR-TKIs, exhibited higher (11)C-PD153035 uptakes than the other cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 87-95 epidermal growth factor receptor Homo sapiens 53-57 26334931-12 2016 In conclusion, (11)C-PD153035 can serve as an EGFR imaging agent in vitro and in vivo, and predicts sensitivity to EGFR-TKIs. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 21-29 epidermal growth factor receptor Homo sapiens 46-50 26334931-12 2016 In conclusion, (11)C-PD153035 can serve as an EGFR imaging agent in vitro and in vivo, and predicts sensitivity to EGFR-TKIs. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 21-29 epidermal growth factor receptor Homo sapiens 115-119 24639330-8 2015 Pretreatment with EGFR inhibitors AG1478 and PD153035 significantly limited Pb(2+) -induced reduction in DNMT3a mRNA. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 45-53 epidermal growth factor receptor Homo sapiens 18-22 25482018-11 2015 Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 130-138 epidermal growth factor receptor Homo sapiens 80-112 25482018-11 2015 Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 130-138 epidermal growth factor receptor Homo sapiens 114-118 25482018-11 2015 Ascites-induced migration and a cMet phosphorylation were strongly inhibited by epidermal growth factor receptor (EGFR) inhibitor PD153035, suggesting the transactivation of cMet by EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 130-138 epidermal growth factor receptor Homo sapiens 182-186 23765435-8 2015 Epidermal growth factor receptor (EGFR) inhibitors AG1478 and PD153035 reduced both transcription and phosphorylation by extracellular signal-regulated kinase (ERK1/2). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 62-70 epidermal growth factor receptor Homo sapiens 0-32 23765435-8 2015 Epidermal growth factor receptor (EGFR) inhibitors AG1478 and PD153035 reduced both transcription and phosphorylation by extracellular signal-regulated kinase (ERK1/2). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 62-70 epidermal growth factor receptor Homo sapiens 34-38 25329617-7 2014 We discovered that epidermal growth factor receptor (EGFR) trans-activation mediated FLZ-induced AKT activation and the pro-survival effect in RPE cells, and the anti-apoptosis effect of FLZ against H2O2 was inhibited by the EGFR inhibitor, PD153035, or by EGFR shRNA-knockdown. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 241-249 epidermal growth factor receptor Homo sapiens 19-51 25329617-7 2014 We discovered that epidermal growth factor receptor (EGFR) trans-activation mediated FLZ-induced AKT activation and the pro-survival effect in RPE cells, and the anti-apoptosis effect of FLZ against H2O2 was inhibited by the EGFR inhibitor, PD153035, or by EGFR shRNA-knockdown. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 241-249 epidermal growth factor receptor Homo sapiens 53-57 22735833-5 2012 EGFR and ERK phosphorylation induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and U0126 (ERK inhibitor), respectively. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 74-82 epidermal growth factor receptor Homo sapiens 0-4 22974583-5 2012 We further found that epidermal growth factor (EGF) receptor up-regulates Kaiso at the RNA and protein levels in prostate cancer cell lines, but more interestingly causes a shift of cytoplasmic Kaiso to the nucleus that is reversed by the EGF receptor-specific kinase inhibitor, PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 279-287 epidermal growth factor receptor Homo sapiens 22-60 22974583-5 2012 We further found that epidermal growth factor (EGF) receptor up-regulates Kaiso at the RNA and protein levels in prostate cancer cell lines, but more interestingly causes a shift of cytoplasmic Kaiso to the nucleus that is reversed by the EGF receptor-specific kinase inhibitor, PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 279-287 epidermal growth factor receptor Homo sapiens 239-251 25124631-6 2014 An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 26-34 epidermal growth factor receptor Homo sapiens 3-7 25124631-6 2014 An EGFR kinase inhibitor, PD153035, blocked EGF-induced AQP8 expression and cell migration and AQP8 expression was decreased from 1.59-fold (EGF-treated) to 0.43-fold (PD153035-treated) in SiHa. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 168-176 epidermal growth factor receptor Homo sapiens 3-7 24335566-0 2014 A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 68-76 epidermal growth factor receptor Homo sapiens 17-21 24335566-7 2014 The SUVmax/WM (11C-PD153035 uptake in the white matter of the contralateral normal hemisphere) ratio was used to indicate the EGFR expression level in the ROI in PET/CT, and it was correlated with the EGFR expression detected by IHC and western blot analysis. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 19-27 epidermal growth factor receptor Homo sapiens 126-130 24354805-6 2013 Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more sensitive to the EGFR-targeted TKIs lapatinib and PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 140-148 epidermal growth factor receptor Homo sapiens 107-111 22797910-8 2012 The EGFR tyrosine kinase inhibitor PD153035 reversed the elevated proliferation seen in the absence of SHP-1. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 35-43 epidermal growth factor receptor Homo sapiens 4-8 22735833-5 2012 EGFR and ERK phosphorylation induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and U0126 (ERK inhibitor), respectively. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 74-82 epidermal growth factor receptor Homo sapiens 84-88 22517768-8 2012 The EGFR tyrosine kinase inhibitor PD153035 also abolished 2fLI-induced COX-2 expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 35-43 epidermal growth factor receptor Homo sapiens 4-8 21472131-8 2011 Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2-dependent proliferation and EGFR/ERK responses. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 217-225 epidermal growth factor receptor Homo sapiens 185-189 21964676-9 2012 Similar results were obtained in DU-145 prostate cancer cells induced to re-express E-cadherin in hepatocyte coculture or following chemical induction by the GnRH agonist buserelin or the EGFR inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 203-211 epidermal growth factor receptor Homo sapiens 188-192 22613406-3 2012 This study investigated the therapeutic and preventive effects of an inhibitor of EGFR (PD153035) on OSCC. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 89-97 epidermal growth factor receptor Homo sapiens 83-87 22613406-7 2012 PD153035 inhibited the DMBA-induced increases in cell proliferation and in levels of phosphorylated EGFR and phosphorylated signal transducer and activator of transcription 3 (STAT3) protein in the hamster cheek pouch. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 100-104 22613406-8 2012 CONCLUSIONS: Inhibitors of EGFR, such as PD153035, have potential value in the treatment and prevention of OSCC. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 41-49 epidermal growth factor receptor Homo sapiens 27-31 21820892-11 2011 On the basis of the inhibitor concentration dependent electrochemical signal, the half-maximal inhibition value IC(50) of three EGFR inhibitors, PD-153035, OSI-774 and ZD-1839, and their corresponding inhibition constants K(i) were estimated, which were in agreement with those obtained from the conventional kinase assay. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 145-154 epidermal growth factor receptor Homo sapiens 128-132 21435385-7 2011 NF-kappaB inhibitor BAY 11-7082 suppressed Pb2+-induced COX-2 mRNA expression, and EGFR inhibitors AG1478 and PD153035 as well as EGFR small interfering RNA reduced the coincident nuclear translocation of NF-kappaB. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 110-118 epidermal growth factor receptor Homo sapiens 83-87 22712848-7 2012 PD153035 (10 muM), an epidermal growth factor (EGF) receptor antagonist, attenuated the PM2.5-induced elevation in arginase activity and arginase II expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 22-60 21903741-2 2011 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 122-130 epidermal growth factor receptor Homo sapiens 157-189 21903741-2 2011 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 122-130 epidermal growth factor receptor Homo sapiens 191-195 21903741-2 2011 This pilot study examines the correlation of PET using (11)C-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline ((11)C-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 122-130 epidermal growth factor receptor Homo sapiens 281-285 22866118-7 2011 Pre-treatment with the EGFR inhibitor PD153035 was found to markedly enhance ACC phosphorylation, whereas AMP-activated protein kinase (AMPK) activator AICAR was found to marginally enhance ACC phosphorylation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 38-46 epidermal growth factor receptor Homo sapiens 23-27 21472131-8 2011 Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2-dependent proliferation and EGFR/ERK responses. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 217-225 epidermal growth factor receptor Homo sapiens 185-189 20641571-13 2004 A novel small molecule, 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), has been reported to be a potent tyrosine kinase inhibitor preventing EGFR activation and thus inhibiting proliferation of cancer cells (14). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 71-79 epidermal growth factor receptor Homo sapiens 152-156 20538380-3 2010 This work describes the synthesis and initial tumor affinity testing of the EGFR antagonist (123)I-mAb425 and the EGF receptor tyrosine kinase (EGFR-TK) inhibitor (123)I-PD153035 as potential imaging probes for studying EGFR-expressing prostate cancer using single photon emission tomography. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 170-178 epidermal growth factor receptor Homo sapiens 144-148 20538380-3 2010 This work describes the synthesis and initial tumor affinity testing of the EGFR antagonist (123)I-mAb425 and the EGF receptor tyrosine kinase (EGFR-TK) inhibitor (123)I-PD153035 as potential imaging probes for studying EGFR-expressing prostate cancer using single photon emission tomography. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 170-178 epidermal growth factor receptor Homo sapiens 144-148 20538380-4 2010 METHODS: (123)I-mAb425 and (123)I-PD153035 were prepared, starting from the IgG2a antibody and EGFR antagonist mAb425, that binds to the external domain of the EGF receptors, and from the EGFR-TK inhibitor PD153035, targeting the intra-endothelial tyrosine kinase domain of the EGFR, respectively. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 34-42 epidermal growth factor receptor Homo sapiens 95-99 21130075-2 2011 Recently, PD153035, brominated anilinoquinazoline, has been reported to be not only a highly selective inhibitor of epidermal growth factor receptor but also a DNA intercalator. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 10-18 epidermal growth factor receptor Homo sapiens 116-148 20882990-6 2010 We further showed that the secretory changes of APP and cystatin C in CNE-2 after TGF-alpha stimulation could be abrogated by pretreatment of EGFR tyrosine kinase inhibitor PD153035 and PI3 kinase inhibitor Wortmannin, validating that APP and cystatin C are EGFR-regulated secreted proteins in NPC cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 173-181 epidermal growth factor receptor Homo sapiens 142-146 19804359-6 2009 These downstream phosphorylation events can be inhibited by treatment with the EGFR kinase inhibitor PD 153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 101-110 epidermal growth factor receptor Homo sapiens 79-83 19376214-7 2009 Furthermore, NaF-induced COX-2 expression was markedly suppressed by the Src family kinase (SFK) inhibitor PP2, but only partially suppressed by the epidermal growth factor receptor (EGFR) inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 199-207 epidermal growth factor receptor Homo sapiens 149-181 19376214-7 2009 Furthermore, NaF-induced COX-2 expression was markedly suppressed by the Src family kinase (SFK) inhibitor PP2, but only partially suppressed by the epidermal growth factor receptor (EGFR) inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 199-207 epidermal growth factor receptor Homo sapiens 183-187 20641571-14 2004 PD153035 reversibly binds to the inner membrane ATP-binding domain on EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 70-74 20641571-15 2004 [(11)C]PD153035 has been evaluated in vivo as a positron emission tomography (PET) agent to measure EGFR expression in tumors. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 7-15 epidermal growth factor receptor Homo sapiens 100-104 18802922-3 2008 Treatment of confluent HGE-17 cells with the phosphatidylinositol 3-kinase inhibitor, LY294002, and the epidermal growth factor receptor inhibitor, PD153035, strongly reduced basal and TGFalpha-stimulated cell spreading. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 148-156 epidermal growth factor receptor Homo sapiens 104-136 19133285-7 2009 Specific pharmacological inhibitors, PD153035 for epidermal growth factor receptor (EGFR) and SU6656 for Src family tyrosine kinases (SFK), but not AG1296 for platelet-derived growth factor receptor, could suppress the Pb-induced tyrosine kinases, PKCalpha, Ras-GTP, phospho-Raf-1(S338) and phospho-ERK1/2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 37-45 epidermal growth factor receptor Homo sapiens 50-82 19133285-7 2009 Specific pharmacological inhibitors, PD153035 for epidermal growth factor receptor (EGFR) and SU6656 for Src family tyrosine kinases (SFK), but not AG1296 for platelet-derived growth factor receptor, could suppress the Pb-induced tyrosine kinases, PKCalpha, Ras-GTP, phospho-Raf-1(S338) and phospho-ERK1/2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 37-45 epidermal growth factor receptor Homo sapiens 84-88 18400375-9 2008 Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 28-36 epidermal growth factor receptor Homo sapiens 117-121 19069650-6 2008 Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 54-62 epidermal growth factor receptor Homo sapiens 213-217 19069650-6 2008 Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 54-62 epidermal growth factor receptor Homo sapiens 39-43 18400375-5 2008 EGFR tyrosine kinase inhibitors, such as PD153035, AG1478, as well as non-specific tyrosine kinase inhibitor PP2 cannot reverse EGF-induced down-regulation of EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 41-49 epidermal growth factor receptor Homo sapiens 0-4 18400375-6 2008 These findings thus permit us to develop the following exciting but unconventional strategy to sensitize cancer cells, namely, by priming ovarian cancer cells with EGF and EGFR inhibitor PD153035, before chemotherapy. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 187-195 epidermal growth factor receptor Homo sapiens 172-176 18400375-9 2008 Further studies showed that PD153035, which does not reverse ligand-induced EGFR down-regulation, blocks EGF-induced EGFR activation as well as EGFR"s binding to c-cbl and Grb2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 28-36 epidermal growth factor receptor Homo sapiens 117-121 18986098-5 2008 Leptin stimulated proliferation in four OAC lines expressing leptin receptors (OE33, OE19, BIC-1 and FLO) and this was abolished by specific EGFR inhibitors (PD153035 and AG1478). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 158-166 epidermal growth factor receptor Homo sapiens 141-145 18636178-8 2008 PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 13-17 17882547-7 2008 Treatment of the EGFR positive lines with the EGFR inhibitor PD153035 and amphiregulin-neutralizing antibodies reduced PTHrP mRNA levels by 50-70%. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 61-69 epidermal growth factor receptor Homo sapiens 17-21 17882547-7 2008 Treatment of the EGFR positive lines with the EGFR inhibitor PD153035 and amphiregulin-neutralizing antibodies reduced PTHrP mRNA levels by 50-70%. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 61-69 epidermal growth factor receptor Homo sapiens 46-50 18346929-11 2008 Inhibition of epidermal growth factor receptor activation by PD153035 blocked extracellular signal-regulated kinase phosphorylation and restored Abeta1-40 levels. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 61-69 epidermal growth factor receptor Homo sapiens 14-46 17608728-0 2007 The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 59-67 epidermal growth factor receptor Homo sapiens 16-48 17608728-1 2007 We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 100-108 epidermal growth factor receptor Homo sapiens 34-66 17608728-1 2007 We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 100-108 epidermal growth factor receptor Homo sapiens 68-72 17608728-1 2007 We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 100-108 epidermal growth factor receptor Homo sapiens 249-253 17608728-1 2007 We have previously shown that the epidermal growth factor-receptor (EGFR) tyrosine kinase inhibitor PD153035 induces retinoic acid receptor-beta (RAR-beta) expression in malignant cells by mechanisms that are independent of its blocking activity on EGFR (ErbB1) or on any other ErbB receptor (ErbB2, ErbB3, ErbB4). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 100-108 epidermal growth factor receptor Homo sapiens 255-260 17608728-4 2007 Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 45-53 epidermal growth factor receptor Homo sapiens 30-34 17627611-7 2007 The present study showed that whether in vitro or ex vivo the uptake of (11)C-PD153035 closely correlated with EGFR expression levels. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 78-86 epidermal growth factor receptor Homo sapiens 111-115 17934341-7 2007 Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 58-66 epidermal growth factor receptor Homo sapiens 71-75 17934341-7 2007 Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 58-66 epidermal growth factor receptor Homo sapiens 169-173 17934341-14 2007 PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 13-17 17934341-14 2007 PD153035, an EGFR inhibitor, as well as alpha-NF significantly reduced ERK phosphorylation, suggesting that ERK activation by TCDD was mediated by both EGFR and AhR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 152-156 17533397-6 2007 Parathyroid hormone-related protein gene expression in both lines was reduced 40-80% after treatment with 1 muM of EGFR tyrosine kinase inhibitor PD153035 and precipitating antibodies to AREG. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 146-154 epidermal growth factor receptor Homo sapiens 115-119 17624262-2 2007 However it is still unclear whether (11)C-PD153035 uptake correlates with EGFR expression levels. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 42-50 epidermal growth factor receptor Homo sapiens 74-78 17624262-3 2007 The objective of this study was to investigate the relationship between (11)C-PD153035 accumulation and EGFR expression levels. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 78-86 epidermal growth factor receptor Homo sapiens 104-108 17624262-13 2007 CONCLUSIONS: The uptake of PET tracer (11)C-PD153035 closely correlates with the EGFR expression levels in tumor cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 44-52 epidermal growth factor receptor Homo sapiens 81-85 17028263-5 2007 Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 91-100 epidermal growth factor receptor Homo sapiens 14-46 17286282-0 2007 Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 94-102 epidermal growth factor receptor Homo sapiens 51-83 17286282-4 2007 The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 21-29 epidermal growth factor receptor Homo sapiens 4-10 17286282-4 2007 The ErbB-1 inhibitor PD153035 cooperates with retinoic acid during growth inhibition and induces retinoic acid receptor-beta suggesting that ErbB-1 controls retinoic acid receptor-beta. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 21-29 epidermal growth factor receptor Homo sapiens 4-8 17286282-6 2007 PD153035 inhibits ErbB-1-phosphorylation, whereas its derivative EBE-A22 is inactive. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 18-22 17286282-15 2007 Thus PD153035 induces retinoic acid receptor-beta by ErbB-independent transcriptional and post-transcriptional mechanisms. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 5-13 epidermal growth factor receptor Homo sapiens 53-57 17293597-7 2007 When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 78-86 epidermal growth factor receptor Homo sapiens 91-123 17293597-7 2007 When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 78-86 epidermal growth factor receptor Homo sapiens 125-129 16837130-4 2007 Our results demonstrated that both EGFR inhibitors inhibited tumor cell growth in a dose-dependent manner, but ANAPD was more potent than PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 138-146 epidermal growth factor receptor Homo sapiens 35-39 16837130-8 2007 In conclusion, this study demonstrated that both PD153035 and ANAPD inhibit tumor cell growth in HCC through inhibition of EGFR signaling pathway, and ANAPD is a more potent inhibitor than PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 49-57 epidermal growth factor receptor Homo sapiens 123-127 17028263-5 2007 Inhibition of epidermal growth factor receptor (EGFR) and Src activities by the inhibitors PD-153035 and PP2, respectively, abolished the activation of Stat3 by DEP, suggesting that Stat3 activation by DEP requires EGFR and Src kinase activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 91-100 epidermal growth factor receptor Homo sapiens 48-52 24557623-11 2007 PD153035, a selective inhibitor of EGFR tyrosine kinase, inhibited the TfR protein expression in UVB-treated cells in a dose-dependent manner (P < 0.05). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 35-39 16848764-6 2006 Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 54-62 epidermal growth factor receptor Homo sapiens 16-20 16956907-7 2007 Inhibition of EGFR by specific inhibitors PD153035 or ZD1839 increased susceptibility to I3C-induced apoptosis of MCF7, MDA-MB-468 and MDA-MB-231 cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 42-50 epidermal growth factor receptor Homo sapiens 14-18 16848764-6 2006 Furthermore, an EGFR (EGF receptor) kinase inhibitor, PD153035, blocked EGF-induced AQP3 expression and cell migration. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 54-62 epidermal growth factor receptor Homo sapiens 22-34 16964427-8 2006 We also observed that UV radiation induced activation of EGFR in a time- and dose-dependent manner which was inhibited by EGFR inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 137-145 epidermal growth factor receptor Homo sapiens 57-61 17154492-3 2006 The novel molecules were synthesized by combining the structural features of the EGFR inhibitor PD153035 (1) and lipoic acid, which among other therapeutic effects triggers apoptosis in human cancer cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 96-104 epidermal growth factor receptor Homo sapiens 81-85 16964427-8 2006 We also observed that UV radiation induced activation of EGFR in a time- and dose-dependent manner which was inhibited by EGFR inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 137-145 epidermal growth factor receptor Homo sapiens 122-126 16964427-10 2006 EGFR kinase inhibitor, PD153035, inhibited UV-induced HIF-1alpha and VEGF protein expression in a dose-dependent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 23-31 epidermal growth factor receptor Homo sapiens 0-4 16773209-6 2006 TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 156-164 epidermal growth factor receptor Homo sapiens 26-30 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 123-131 epidermal growth factor receptor Homo sapiens 69-73 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 123-131 epidermal growth factor receptor Homo sapiens 107-111 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 123-131 epidermal growth factor receptor Homo sapiens 107-111 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 237-245 epidermal growth factor receptor Homo sapiens 69-73 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 237-245 epidermal growth factor receptor Homo sapiens 107-111 16969513-8 2006 Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 237-245 epidermal growth factor receptor Homo sapiens 107-111 16773209-6 2006 TSA transiently activated EGFR tyrosine phosphorylation and AKT activation in a time- and dose-dependent manner, which had been inhibited by EGFR inhibitor PD153035 and PI3 kinase inhibitor LY294002. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 156-164 epidermal growth factor receptor Homo sapiens 141-145 16773209-7 2006 We also observed that TSA transiently induced survivin expression that had been inhibited by PD153035 and LY294002, suggesting that TSA-induced survivin expression is mediated by EGFR/PI3 kinase pathway. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 93-101 epidermal growth factor receptor Homo sapiens 179-183 16410015-5 2006 Zn2+-mediated EGFR phosphorylation did not require ligand binding and was ablated by the EGFR kinase inhibitor PD153035, but not by the Src kinase inhibitor PP2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 111-119 epidermal growth factor receptor Homo sapiens 14-18 16410015-5 2006 Zn2+-mediated EGFR phosphorylation did not require ligand binding and was ablated by the EGFR kinase inhibitor PD153035, but not by the Src kinase inhibitor PP2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 111-119 epidermal growth factor receptor Homo sapiens 89-93 17361080-7 2006 Epidermal growth factor receptor (EGFR) expressed in HaCaT cells was inhibited by PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 0-32 16331686-5 2006 The PGE(2)-induced EGFR phosphorylation and cell invasiveness were blocked by the EP(1) receptor siRNA or antagonist ONO-8711 and by two EGFR tyrosine kinase inhibitors, AG1478 and PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 181-189 epidermal growth factor receptor Homo sapiens 19-23 16300728-6 2006 Furthermore, the epithelial growth factor (EGF) receptor specific inhibitor (PD153035) reduced vanadate-induced COX-2 expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 77-85 epidermal growth factor receptor Homo sapiens 17-56 16443372-8 2006 An ErbB1 tyrosine kinase inhibitor, PD153035, inhibited the TGFalpha effect. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 36-44 epidermal growth factor receptor Homo sapiens 3-8 17361080-7 2006 Epidermal growth factor receptor (EGFR) expressed in HaCaT cells was inhibited by PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 34-38 15952178-6 2005 The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 59-63 16211241-6 2005 Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 77-85 epidermal growth factor receptor Homo sapiens 61-65 16211241-8 2005 Paclitaxel-induced survivin expression was inhibited by the EGFR inhibitor, PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 76-84 epidermal growth factor receptor Homo sapiens 60-64 16077934-10 2005 Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 31-39 epidermal growth factor receptor Homo sapiens 16-20 16077934-10 2005 Pretreatment of EGFR inhibitor PD153035 blocked BA-induced EGFR phosphorylation, ERK and AKT activation, and survivin expression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 31-39 epidermal growth factor receptor Homo sapiens 59-63 15952178-6 2005 The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 64-69 15952178-6 2005 The effect of HB-EGF was also blocked by the EGF receptor (EGFR/ErbB1) inhibitors PD153035 and PD158780, implicating EGFR in HB-EGF-induced cell proliferation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 117-121 16049334-5 2005 The epidermal growth factor receptor inhibitor PD153035 partially blocked the UVB-mediated induction of MMP-1 and totally abrogated its production after stimulation with either heparin-binding epidermal growth factor-like growth factor or epidermal growth factor. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 47-55 epidermal growth factor receptor Homo sapiens 4-36 15766561-7 2005 Western blotting, colorimetric in vitro cell proliferation assays, and reverse transcription-polymerase chain reaction demonstrated that the EGFR inhibitor PD153035 not only blocked activation of EGFR and inhibited cell growth, but also stimulated RAR-beta expression in MDA-MB-468 breast and OVCAR-3 ovarian carcinoma cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 156-164 epidermal growth factor receptor Homo sapiens 141-145 15985706-3 2005 Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 189-197 epidermal growth factor receptor Homo sapiens 166-170 15867774-0 2005 The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 73-81 epidermal growth factor receptor Homo sapiens 14-46 15867774-4 2005 The purpose of this study is to evaluate the ability of the epidermal growth factor receptor tyrosine kinase inhibitor PD153035 to abrogate the expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 119-127 epidermal growth factor receptor Homo sapiens 60-92 15867774-12 2005 CONCLUSIONS: Epidermal growth factor receptor tyrosine kinase inhibitor PD153035 significantly inhibited motility and invasion in malignant pleural mesothelioma cells in vitro, regardless of their epidermal growth factor receptor expression levels. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 72-80 epidermal growth factor receptor Homo sapiens 13-45 15766561-7 2005 Western blotting, colorimetric in vitro cell proliferation assays, and reverse transcription-polymerase chain reaction demonstrated that the EGFR inhibitor PD153035 not only blocked activation of EGFR and inhibited cell growth, but also stimulated RAR-beta expression in MDA-MB-468 breast and OVCAR-3 ovarian carcinoma cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 156-164 epidermal growth factor receptor Homo sapiens 196-200 15054105-6 2004 The use of a specific EGFR tyrosine kinase inhibitor, PD153035, correlated with PPARgamma dephosphorylation and translocation to the nucleus, indicating a mechanism for regulating the balance between proliferation and differentiation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 54-62 epidermal growth factor receptor Homo sapiens 22-26 15304097-6 2004 Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 24-32 epidermal growth factor receptor Homo sapiens 14-18 15304097-6 2004 Inhibition of EGFR with PD153035 impairs the MbetaCD-induced phosphorylation of EGFR, HER2, and ERK, but does not impair the alteration of K14, K10, or involucrin gene expression, indicating that other signaling proteins regulate this phenomenon. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 24-32 epidermal growth factor receptor Homo sapiens 80-84 15191553-6 2004 EGF-induced induction of nNOS was completely inhibited by the specific EGFR antagonist PD153035 and by the EGFR and Janus kinase 2/3 inhibitor AG490. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 87-95 epidermal growth factor receptor Homo sapiens 71-75 15827339-2 2005 We used cDNA microarrays to examine alterations in gene expression after treatment of carcinoma cells with PD153035, a specific and reversible inhibitor of EGFR function. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 107-115 epidermal growth factor receptor Homo sapiens 156-160 15562758-2 2004 METHODS: The inhibitor of EGFR, PD153035, was used to block the signal transduction of EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 32-40 epidermal growth factor receptor Homo sapiens 26-30 15562758-2 2004 METHODS: The inhibitor of EGFR, PD153035, was used to block the signal transduction of EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 32-40 epidermal growth factor receptor Homo sapiens 87-91 15562758-7 2004 CONCLUSION: The proliferation and survival of myeloma cells may be suppressed by PD153035 due to the blockage of phosphatation of STAT3 induced by the activation of EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 81-89 epidermal growth factor receptor Homo sapiens 165-169 15381832-3 2004 Using [14C]choline-labeled gastric mucosal cells in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on phospholipid release was subject to a dose-dependent suppression by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 230-238 epidermal growth factor receptor Homo sapiens 207-211 15177934-6 2004 The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 135-143 epidermal growth factor receptor Homo sapiens 30-34 12966092-5 2003 The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 73-81 epidermal growth factor receptor Homo sapiens 14-46 15070968-7 2004 When EGF receptor (EGFR) kinase activity was blocked using PD153035, high passage IGFBP-3 transfectants were growth inhibited compared with controls treated with inhibitor. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 59-67 epidermal growth factor receptor Homo sapiens 5-17 15070968-7 2004 When EGF receptor (EGFR) kinase activity was blocked using PD153035, high passage IGFBP-3 transfectants were growth inhibited compared with controls treated with inhibitor. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 59-67 epidermal growth factor receptor Homo sapiens 19-23 14996711-3 2004 Here, we report a protective effect of the EGFR inhibitors AG1478 and PD153035 against cell death induced by acute hypoxia, which contrasts with their proapoptotic effects under normoxia. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 70-78 epidermal growth factor receptor Homo sapiens 43-47 15009100-8 2004 The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 72-80 epidermal growth factor receptor Homo sapiens 4-36 15009100-8 2004 The epidermal growth factor receptor-specific tyrosine kinase inhibitor PD153035 abrogated anthralin-induced epidermal growth factor receptor phosphorylation and activation of extracellular-regulated kinase 1/2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 72-80 epidermal growth factor receptor Homo sapiens 109-141 12966092-5 2003 The selective epidermal growth factor receptor (EGFR) kinase inhibitors, PD153035 and ZD1839 (Iressa), abolished PPARalpha and gamma agonist-dependent Erk activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 73-81 epidermal growth factor receptor Homo sapiens 48-52 14500405-6 2003 In the presence of EGFR-specific tyrosine kinase inhibitor (PD153035) or an anti-EGFR antibody (C225), PLCgamma-1 activation was abrogated indicating that PLCgamma-1 was downstream of EGFR. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 60-68 epidermal growth factor receptor Homo sapiens 19-23 14612544-5 2003 Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 90-98 epidermal growth factor receptor Homo sapiens 48-52 14612544-5 2003 Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 90-98 epidermal growth factor receptor Homo sapiens 156-160 14612544-5 2003 Treatment of our in vitro glioma model with the EGFR kinase inhibitors ZD1839 (Iressa) or PD153035, synthetic anilinoquinazolines with high specificity for EGFR, resulted in significant suppression of EGFR autophosphorylation even with very low levels of drug. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 90-98 epidermal growth factor receptor Homo sapiens 156-160 12943688-3 2003 Heregulin beta1, a ligand of ErbB receptors, enhanced the generation of Nkx2.5/GFP(+) cardiomyocytes in embryoid bodies, while AG1478 and PD153035, inhibitors of ErbBs, drastically blocked the generation of Nkx2.5/GFP(+) cardiomyocytes. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 138-146 epidermal growth factor receptor Homo sapiens 29-33 12915106-7 2003 The EGFR kinase inhibitor PD153035 ablated all phosphorylation induced by EGF but none caused by Zn(2+). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 26-34 epidermal growth factor receptor Homo sapiens 4-8 12876202-9 2003 We demonstrate the future potential of this approach by characterizing the action of the epidermal growth factor receptor inhibitor PD153035 on cells by using Ab arrays; direct scale-up to array-based screening in 96- and 384-well plates should allow small molecules to be identified with specific inhibitory profiles against a signaling network. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 132-140 epidermal growth factor receptor Homo sapiens 89-121 12794766-1 2003 Our results revealed that the blockade of epidermal growth factor receptor (EGFR) tyrosine kinase and protein kinase A (PKA) signaling pathways by specific inhibitors (PD153035 and Rp-cAMPs) leads to a synergistic inhibition of EGF- and serum-stimulated growth of human prostatic cancer cells (LNCaP, DU145 and PC3) concomitant with an arrest in the G1 phase of cellular cycle. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 168-176 epidermal growth factor receptor Homo sapiens 42-74 12794766-1 2003 Our results revealed that the blockade of epidermal growth factor receptor (EGFR) tyrosine kinase and protein kinase A (PKA) signaling pathways by specific inhibitors (PD153035 and Rp-cAMPs) leads to a synergistic inhibition of EGF- and serum-stimulated growth of human prostatic cancer cells (LNCaP, DU145 and PC3) concomitant with an arrest in the G1 phase of cellular cycle. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 168-176 epidermal growth factor receptor Homo sapiens 76-80 12915106-8 2003 PD153035 abolished EGF-induced phosphorylation of the EGFR substrate Cbl, but had no effect on levels of phospho-Cbl caused by Zn(2+). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 54-58 12594213-3 2003 The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 249-257 epidermal growth factor receptor Homo sapiens 34-66 12733059-10 2003 Potent specific EGFR inhibitors, such as PD153035 and Tyrphostin 25, as well as Calphostin C, an inhibitor of PKC, significantly blocked the effect of TPA on AJs. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 41-49 epidermal growth factor receptor Homo sapiens 16-20 12594213-3 2003 The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 249-257 epidermal growth factor receptor Homo sapiens 68-72 12594213-3 2003 The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 249-257 epidermal growth factor receptor Homo sapiens 114-118 12594213-3 2003 The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilinoquinazoline inhibitors such as PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 249-257 epidermal growth factor receptor Homo sapiens 114-118 11943650-7 2002 Pertussis toxin and two specific epidermal growth factor receptor (EGFR) inhibitors (AG-1478 and PD-153035) prevented the stretch-induced ERK1/2 activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 97-106 epidermal growth factor receptor Homo sapiens 33-65 12171571-2 2002 PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-9 epidermal growth factor receptor Homo sapiens 145-149 12171571-2 2002 PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 11-54 epidermal growth factor receptor Homo sapiens 145-149 11943669-4 2002 Each metal significantly increased Ras activity, and this effect was inhibited by the EGFR tyrosine kinase activity inhibitor PD-153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 126-135 epidermal growth factor receptor Homo sapiens 86-90 11992543-7 2002 EGFR antagonist PD153035 and anti-EGFR antibody C225 completely inhibited EGF-induced reporter activity and cytokine expression, but only partially inhibited constitutive activity. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 16-24 epidermal growth factor receptor Homo sapiens 0-4 11943650-7 2002 Pertussis toxin and two specific epidermal growth factor receptor (EGFR) inhibitors (AG-1478 and PD-153035) prevented the stretch-induced ERK1/2 activation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 97-106 epidermal growth factor receptor Homo sapiens 67-71 11562388-5 2001 In some experiments, EGFR kinase activity in parental cells was inhibited by treatment with PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 92-100 epidermal growth factor receptor Homo sapiens 21-25 11792073-8 2002 Intravascular administration of human EGF increased Ppa, and pretreatment with PD153035, an EGF receptor-specific tyrosine kinase inhibitor, attenuated ROFA-induced pulmonary vasoconstriction. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 79-87 epidermal growth factor receptor Homo sapiens 92-104 11879570-4 2001 Evidence is provided that phosphorylation and activation of p70(S6K)/p90(RSK) induced by UVA were prevented in Egfr(-/-) cells and were also markedly inhibited by the EGFR-specific tyrosine kinase inhibitors AG1478 and PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 219-227 epidermal growth factor receptor Homo sapiens 167-171 11822173-1 2001 The 4-anilinoquinazoline PD 153035 (1) is a potential antitumor agent which acts by inhibiting tyrosine kinase activity of epidermal growth factor receptor (EFGR) via competitive binding at the ATP site of enzyme. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 25-34 epidermal growth factor receptor Homo sapiens 123-155 11431328-2 2001 Although the EGFR-specific antagonist PD153035 increased caspase-3 activity, this was independent of FAK activity. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 38-46 epidermal growth factor receptor Homo sapiens 13-17 10911738-3 2000 The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 28-36 epidermal growth factor receptor Homo sapiens 13-17 11178955-2 2001 AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 11-19 epidermal growth factor receptor Homo sapiens 72-77 11178955-2 2001 AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 11-19 epidermal growth factor receptor Homo sapiens 125-130 11257459-6 2001 In all cases, EGFR tyrosine phosphorylation was completely inhibited by pretreatment of PD153035 (100 nM, 1 h). 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 88-96 epidermal growth factor receptor Homo sapiens 14-18 10962438-5 2000 The anti-EGFR monoclonal antibody (MAb) 225 and the EGFR tyrosine kinase inhibitor PD153035 blocked anchorage-independent growth of Ha-ras transformed cells in soft agar and were more effective when used in combination. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 83-91 epidermal growth factor receptor Homo sapiens 52-56 11179516-8 2001 EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 30-38 epidermal growth factor receptor Homo sapiens 0-12 11179516-8 2001 EGF receptor kinase inhibitor PD153035 and AG1478 inhibited IL-1 beta-induced EGF receptor tyrosine phosphorylation. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 30-38 epidermal growth factor receptor Homo sapiens 78-90 10970776-4 2000 The Src-family tyrosine kinase inhibitor PP1, as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR TK) by PD153035, also blocks PYY stimulation of MAPK. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 146-154 epidermal growth factor receptor Homo sapiens 84-116 10970776-4 2000 The Src-family tyrosine kinase inhibitor PP1, as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR TK) by PD153035, also blocks PYY stimulation of MAPK. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 146-154 epidermal growth factor receptor Homo sapiens 134-138 10911738-3 2000 The specific EGFR inhibitor PD153035 markedly decreased UVB-induced phosphorylation of EGFR, ERK1/2 and shc, whereas p38 activation was unaffected. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 28-36 epidermal growth factor receptor Homo sapiens 87-91 10564177-7 1999 Furthermore, the EGF receptor-specific tyrosine kinase inhibitor (PD-153035) significantly blocked the phosphorylation of MEK1/2 initiated by metals. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 66-75 epidermal growth factor receptor Homo sapiens 17-29 10601294-5 1999 These effects were attenuated by EGFR tyrosine kinase inhibitor PD153035 or an anti-EGFR monoclonal antibody, whereas protein kinase C inhibitors H7 and bisindolylmaleimide I or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 abolished profilaggrin up-regulation but not K10 suppression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 64-72 epidermal growth factor receptor Homo sapiens 33-37 10583160-4 1999 SU5271 potently inhibits ligand-induced autophosphorylation of EGFR, and downstream signal transduction events, including DNA replication and cell cycle progression. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-6 epidermal growth factor receptor Homo sapiens 63-67 10583160-5 1999 SU5271, at micromolar concentrations, inhibited the proliferation of keratinocytes isolated from psoriatic lesions in excellent correlation with its EGFR kinase inhibitory activity in these cells. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-6 epidermal growth factor receptor Homo sapiens 149-153 10318765-10 1999 The EGF-induced increase in the erbB2 cluster size was inhibited by the EGFR-specific tyrosine kinase inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 112-120 epidermal growth factor receptor Homo sapiens 72-76 10473113-9 1999 PD153035 reduced invasiveness to levels similar to those seen with U73122, suggesting that the autocrine EGFR stimulatory loop is functioning to promote invasiveness. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 105-109 9664130-4 1998 Using the EGFR-overexpressing head and neck carcinoma cell line HN5, we have compared the biological consequences of treatment with an inhibitor of EGFR tyrosine kinase (PD153035) with anti-EGFR monoclonal antibodies (mAbs) ICR63 or ICR80. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 170-178 epidermal growth factor receptor Homo sapiens 148-152 10621850-4 1999 We tested the in vitro therapeutic efficacy of PD153035--a potent, specific inhibitor of the tyrosine kinase intrinsic to the EGF receptor--by employing a well-characterized cell line derived from human gingival SCCHN. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 47-55 epidermal growth factor receptor Homo sapiens 126-138 10621850-6 1999 PD153035, at nanomolar concentrations, inhibited autophosphorylation of the EGF receptor induced by EGF stimulation and the inhibition occurred in a dose-dependent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 76-88 9856822-4 1998 CaN19 was strongly induced after 24 h of organ culture, and its induction could be blocked by PD153035, a specific inhibitor of EGF receptor tyrosine kinase activity. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 94-102 epidermal growth factor receptor Homo sapiens 128-140 9664130-4 1998 Using the EGFR-overexpressing head and neck carcinoma cell line HN5, we have compared the biological consequences of treatment with an inhibitor of EGFR tyrosine kinase (PD153035) with anti-EGFR monoclonal antibodies (mAbs) ICR63 or ICR80. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 170-178 epidermal growth factor receptor Homo sapiens 148-152 9558281-3 1998 We therefore examined the effects of a selective EGFR tyrosine kinase inhibitor, PD 153035, on proliferation and survival of five colon cancer cell lines whose autonomous proliferation is either EGFR ligand dependent or EGFR ligand independent. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 81-90 epidermal growth factor receptor Homo sapiens 49-53 9558281-8 1998 CONCLUSIONS: The EGFR tyrosine kinase inhibitor PD 153035 induces cytostasis and caspase-dependent apoptosis in EGFR ligand-dependent colon cancer cell lines. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 48-57 epidermal growth factor receptor Homo sapiens 17-21 9558281-8 1998 CONCLUSIONS: The EGFR tyrosine kinase inhibitor PD 153035 induces cytostasis and caspase-dependent apoptosis in EGFR ligand-dependent colon cancer cell lines. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 48-57 epidermal growth factor receptor Homo sapiens 112-116 9580112-3 1998 Here we report that human keratinocytes undergo apoptosis when incubated with the blocking EGFR monoclonal antibody 225 IgG, or PD153035, a highly specific EGFR tyrosine kinase inhibitor. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 128-136 epidermal growth factor receptor Homo sapiens 156-160 9815602-0 1997 PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 48-80 9462709-5 1998 Both increased as well as reduced EGF-dependent adhesion could be blocked using either ligand-blocking monoclonal antibody 14E1 or the potent EGFR tyrosine kinase inhibitor PD 153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 173-182 epidermal growth factor receptor Homo sapiens 142-146 9406816-3 1997 We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 227-236 epidermal growth factor receptor Homo sapiens 79-111 9406816-3 1997 We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 227-236 epidermal growth factor receptor Homo sapiens 113-117 9406816-3 1997 We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 227-236 epidermal growth factor receptor Homo sapiens 121-126 9406816-3 1997 We present evidence that selected inhibitors of activation of the type I human epidermal growth factor receptor (EGFR or HER-1), namely, neutralizing monoclonal antibody to HER-1/EGFR and the specific tyrosine kinase inhibitor PD 153035, potently inhibit proliferation of human keratinocytes in autonomously replicating subconfluent cultures. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 227-236 epidermal growth factor receptor Homo sapiens 173-178 9815602-1 1997 PD153035 is reported to be a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase and, to a lesser degree, of the closely related HER2/neu receptor. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 66-104 34885111-7 2021 Treatment with PD153035, an EGFR inhibitor, revealed altered CRC expression of PD-L1 but only in gels lacking MSCs. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 15-23 epidermal growth factor receptor Homo sapiens 28-32 9276746-6 1997 The highly EGF receptor-specific tyrosine kinase inhibitor PD153035 strongly inhibited induction of all four transcripts in organ culture, as well as release of immunoreactive HB-EGF into the medium. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 59-67 epidermal growth factor receptor Homo sapiens 11-23 8824347-1 1996 PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 63-101 8824347-1 1996 PD153035 is a potent (Ki = 6 pm) and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase that suppresses tyrosine phosphorylation of the EGF receptor in A431 cells at nanomolar concentrations in cell culture. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 0-8 epidermal growth factor receptor Homo sapiens 166-178 8066447-1 1994 A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 24-33 epidermal growth factor receptor Homo sapiens 48-86 30290164-7 2019 Pharmacologic inhibition of EGFR-signaling using PD153035 inhibited TGFbeta-induced EMT, including the upregulation of mesenchymal markers and downregulation of epithelial markers. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 49-57 epidermal growth factor receptor Homo sapiens 28-32 32236267-7 2021 More importantly, compared with a standard EGFR-TKI, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), F-MPG and OH-MPG showed stronger tumor inhibition in preclinical models. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 98-106 epidermal growth factor receptor Homo sapiens 43-47 31936670-4 2020 In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 162-170 epidermal growth factor receptor Homo sapiens 85-117 31936670-4 2020 In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 162-170 epidermal growth factor receptor Homo sapiens 119-123 31936670-4 2020 In this study, we demonstrate that scratch injury upregulates the phosphorylation of epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent, and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein kinase (MAPK)-independent manner. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 162-170 epidermal growth factor receptor Homo sapiens 147-151 29751044-4 2018 Interestingly, overexpression of EGFR or treatment with EGF decreases miR-200c expression and this is reversed after treatment with EGFR specific kinase inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 163-171 epidermal growth factor receptor Homo sapiens 33-37 29751044-4 2018 Interestingly, overexpression of EGFR or treatment with EGF decreases miR-200c expression and this is reversed after treatment with EGFR specific kinase inhibitor PD153035. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 163-171 epidermal growth factor receptor Homo sapiens 132-136 29518481-0 2018 Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 50-58 epidermal growth factor receptor Homo sapiens 0-32 29518481-0 2018 Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 50-58 epidermal growth factor receptor Homo sapiens 34-38 29518481-2 2018 In this study, we conducted in vitro and in vivo experiments to determine whether PD153035, an inhibitor of EGFR, could reverse ABCG2-mediated MDR in human NSCLC and transfected cells overexpressing ABCG2. 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 82-90 epidermal growth factor receptor Homo sapiens 108-112